全文获取类型
收费全文 | 38266篇 |
免费 | 3587篇 |
国内免费 | 2660篇 |
出版年
2023年 | 417篇 |
2022年 | 405篇 |
2021年 | 1414篇 |
2020年 | 1151篇 |
2019年 | 1396篇 |
2018年 | 1354篇 |
2017年 | 970篇 |
2016年 | 1447篇 |
2015年 | 2348篇 |
2014年 | 2644篇 |
2013年 | 2893篇 |
2012年 | 3485篇 |
2011年 | 3228篇 |
2010年 | 1931篇 |
2009年 | 1712篇 |
2008年 | 2085篇 |
2007年 | 1862篇 |
2006年 | 1663篇 |
2005年 | 1360篇 |
2004年 | 1280篇 |
2003年 | 1097篇 |
2002年 | 995篇 |
2001年 | 812篇 |
2000年 | 741篇 |
1999年 | 670篇 |
1998年 | 369篇 |
1997年 | 365篇 |
1996年 | 322篇 |
1995年 | 296篇 |
1994年 | 317篇 |
1993年 | 232篇 |
1992年 | 385篇 |
1991年 | 343篇 |
1990年 | 278篇 |
1989年 | 258篇 |
1988年 | 219篇 |
1987年 | 172篇 |
1986年 | 160篇 |
1985年 | 172篇 |
1984年 | 154篇 |
1983年 | 114篇 |
1982年 | 100篇 |
1981年 | 63篇 |
1980年 | 66篇 |
1979年 | 92篇 |
1978年 | 77篇 |
1977年 | 63篇 |
1976年 | 74篇 |
1975年 | 68篇 |
1974年 | 77篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Michael P. Gustafson Yi Lin Mary L. Maas Virginia P. Van Keulen Patrick B. Johnston Tobias Peikert Dennis A. Gastineau Allan B. Dietz 《PloS one》2015,10(3)
The development of flow cytometric biomarkers in human studies and clinical trials has been slowed by inconsistent sample processing, use of cell surface markers, and reporting of immunophenotypes. Additionally, the function(s) of distinct cell types as biomarkers cannot be accurately defined without the proper identification of homogeneous populations. As such, we developed a method for the identification and analysis of human leukocyte populations by the use of eight 10-color flow cytometric protocols in combination with novel software analyses. This method utilizes un-manipulated biological sample preparation that allows for the direct quantitation of leukocytes and non-overlapping immunophenotypes. We specifically designed myeloid protocols that enable us to define distinct phenotypes that include mature monocytes, granulocytes, circulating dendritic cells, immature myeloid cells, and myeloid derived suppressor cells (MDSCs). We also identified CD123 as an additional distinguishing marker for the phenotypic characterization of immature LIN-CD33+HLA-DR- MDSCs. Our approach permits the comprehensive analysis of all peripheral blood leukocytes and yields data that is highly amenable for standardization across inter-laboratory comparisons for human studies. 相似文献
2.
A common problem that is encountered in medical applications is the overall homogeneity of survival distributions when two survival curves cross each other. A survey demonstrated that under this condition, which was an obvious violation of the assumption of proportional hazard rates, the log-rank test was still used in 70% of studies. Several statistical methods have been proposed to solve this problem. However, in many applications, it is difficult to specify the types of survival differences and choose an appropriate method prior to analysis. Thus, we conducted an extensive series of Monte Carlo simulations to investigate the power and type I error rate of these procedures under various patterns of crossing survival curves with different censoring rates and distribution parameters. Our objective was to evaluate the strengths and weaknesses of tests in different situations and for various censoring rates and to recommend an appropriate test that will not fail for a wide range of applications. Simulation studies demonstrated that adaptive Neyman’s smooth tests and the two-stage procedure offer higher power and greater stability than other methods when the survival distributions cross at early, middle or late times. Even for proportional hazards, both methods maintain acceptable power compared with the log-rank test. In terms of the type I error rate, Renyi and Cramér—von Mises tests are relatively conservative, whereas the statistics of the Lin-Xu test exhibit apparent inflation as the censoring rate increases. Other tests produce results close to the nominal 0.05 level. In conclusion, adaptive Neyman’s smooth tests and the two-stage procedure are found to be the most stable and feasible approaches for a variety of situations and censoring rates. Therefore, they are applicable to a wider spectrum of alternatives compared with other tests. 相似文献
3.
Chiao-Fang Teng Wen-Chuan Hsieh Han-Chieh Wu Yih-Jyh Lin Hung-Wen Tsai Wenya Huang Ih-Jen Su 《PloS one》2015,10(4)
Hepatitis B virus (HBV) pre-S2 mutant can induce hepatocellular carcinoma (HCC) via the induction of endoplasmic reticulum stress to activate mammalian target of rapamycin (MTOR) signaling. The association of metabolic syndrome with HBV-related HCC raises the possibility that pre-S2 mutant-induced MTOR activation may drive the development of metabolic disorders to promote tumorigenesis in chronic HBV infection. To address this issue, glucose metabolism and gene expression profiles were analyzed in transgenic mice livers harboring pre-S2 mutant and in an in vitro culture system. The pre-S2 mutant transgenic HCCs showed glycogen depletion. The pre-S2 mutant initiated an MTOR-dependent glycolytic pathway, involving the eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1), Yin Yang 1 (YY1), and myelocytomatosis oncogene (MYC) to activate the solute carrier family 2 (facilitated glucose transporter), member 1 (SLC2A1), contributing to aberrant glucose uptake and lactate production at the advanced stage of pre-S2 mutant transgenic tumorigenesis. Such a glycolysis-associated MTOR signal cascade was validated in human HBV-related HCC tissues and shown to mediate the inhibitory effect of a model of combined resveratrol and silymarin product on tumor growth. Our results provide the mechanism of pre-S2 mutant-induced MTOR activation in the metabolic switch in HBV tumorigenesis. Chemoprevention can be designed along this line to prevent HCC development in high-risk HBV carriers. 相似文献
4.
5.
6.
7.
8.
Duoru Lin Jingjing Chen Zhuoling Lin Xiaoyan Li Xiaohang Wu Erping Long Lixia Luo Bo Zhang Hui Chen Wan Chen Li Zhang Haotian Lin Weirong Chen Yizhi Liu 《PloS one》2015,10(11)
A review of 6 years of hospitalization charts from Zhongshan Ophthalmic Center (ZOC) revealed that congenital cataracts (CC) accounted for 2.39% of all cataract in-patient cases and that the age at surgery was decreasing before the establishment of the Childhood Cataract Program of the Chinese Ministry of Health (CCPMOH) in December 2010. We aimed to investigate data from the 4 years (January 2011 to December 2014) following the establishment of the CCPMOH, compared, and combined with data from the previous study period (January 2005 to December 2010) to generate a 10-year overview of the hospital-based prevalence and treatment of CC. In the 4-year period after CCPMOH establishment, the prevalence of CC was 2.01% in all hospitalizations, and was 2.78% in all cataract in-patients. Most of the eligible CC in-patients (71%) lived in south China. The ratio of boys to girls was 1.42:1. Nearly 2/3 of the patients underwent cataract extraction with primary intraocular lens (IOL) implantation at a mean age of 78.40±51.45 months, and cataract extraction surgeries without IOL implantation were performed in the remaining 1/3 of patients at a mean age of 10.03±15.92 months. After CCPMOH establishment, an increased incidence of CC was revealed, and the CC in-patients were younger than the patients in the previous period. The 10-year overview (2421 CC in-patients from 206630 hospitalizations) revealed upward trends in both the number and the prevalence of CC and a further reduction in age at surgery. In conclusion, the data from 4-year period after CCPMOH establishment and the 10-year overview showed upward trends in the hospital-based prevalence of CC cases and a further reduction in age at surgery, likely reflecting the effects of the CCPMOH establishment and providing useful information for further CC studies and a valuable foundation for the prevention and treatment of this cause of childhood blindness. 相似文献
9.
10.